Seaport Therapeutics Reports Q1 2026 Results, $260M IPO Proceeds
Seaport Therapeutics reported Q1 2026 financial results and announced new Phase 1 data for GlyphAgo showing therapeutic exposures without liver enzyme elevation concerns. The company's recent upsized IPO generated $260M in gross proceeds, providing funding runway into 2029 while advancing clinical development of neuropsychiatric programs.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day